NCT02764554 is a clinical trial in Differentiated Thyroid Carcinoma (DTC), sponsored by Eisai Korea Inc..

Who is sponsoring NCT02764554?

NCT02764554 is sponsored by Eisai Korea Inc..

What condition does NCT02764554 study?

NCT02764554 studies Differentiated Thyroid Carcinoma (DTC).

Is NCT02764554 still recruiting?

NCT02764554 is currently completed. Last updated 7 October 2021.

Last reviewed 2021-10-07 · How we verify

NCT02764554

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Marketing Surveillance of Lenvima in Korean Patients

Completed Last updated 7 October 2021

What this trial tests

trial in Differentiated Thyroid Carcinoma (DTC) in 132 participants. Completed in 29 September 2021.

Timeline

10 November 2016

Primary endpoint
29 September 2021

29 September 2021

Quick facts

Lead sponsor	Eisai Korea Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	132
Start date	10 November 2016
Primary completion	29 September 2021
Estimated completion	29 September 2021
Sites	32 locations across South Korea

Conditions studied

Differentiated Thyroid Carcinoma (DTC) — all drugs for Differentiated Thyroid Carcinoma (DTC) →

Sponsor

Eisai Korea Inc. — full company profile →

Who can join

Eligibility, any sex, with Differentiated Thyroid Carcinoma (DTC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.
Ancker OV, Wehland M, Bauer J, Infanger M, et al · · 2017 · cited 48× · PMID 28335429 · DOI 10.3390/ijms18030625

Verify or expand the search:

Other Eisai Korea Inc. trials

Trials by the same sponsor.

NCT06964113 — A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine · Phase 4 · recruiting
NCT06810960 — A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease · recruiting
NCT06625242 — A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis · Phase 4 · active not recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02764554 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Korea Inc.
Last refreshed: 7 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02764554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing